HMGA2 gene is a promising target for ovarian cancer silencing therapy.
Ovarian cancer is one of the most lethal gynecological malignancies and the small success rate of routine therapeutic methods justifies efforts to develop new approaches. Evaluation of targets for effective inhibition of ovarian cancer cell growth should precipitate clinical application of gene silencing therapy. In our previous work, we showed upregulation of HMGA2 gene expression as a result of Ras-induced rat ovarian surface epithelial cell transformation. This gene codes the HMGA2 protein, a member of the high-mobility group AT-hook (HMGA) family of nonhistone chromatin proteins. Genome-wide studies revealed upregulation of the HMGA2 gene in human ovarian carcinomas. Herein we have evaluated over-expression of the HMGA2 gene, relevant to ovarian cancer, in subsets of human specimens and cell lines by in situ RNA hybridization and RT-PCR. Transient silencing of HMGA2 gene by means of siRNA inhibited proliferation of those ovarian cancer cells, which over-express this gene initially. Growth suppression was mediated by cell-cycle arrest. Stable silencing of highly expressed HMGA2 gene by shRNAi in A27/80, Ovcar-3 and OAW-42 ovarian cancer cell lines resulted in growth inhibition because of G1 arrest and increase of apoptosis as well. The tumor growth inhibition effect of HMGA2 silencing for Ovcar-3 cells was validated in vivo. Our findings revealed that the HMGA2 gene represents a promising target for gene silencing therapy in ovarian cancer.
Malek
Anastasia
A
Department of Pharmacology and Toxicology, Philipps-University School of Medicine, Marburg, Germany.
Bakhidze
Elena
E
Department of Oncogynecology, N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia.
Noske
Aurelia
A
Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany.
Sers
Christine
C
Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany.
Aigner
Achim
A
Department of Pharmacology and Toxicology, Philipps-University School of Medicine, Marburg, Germany.
Schäfer
Reinhold
R
Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany.
Tchernitsa
Oleg
O
Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany.
D000818:Animals; D017209:Apoptosis; D015153:Blotting, Western; D002277:Carcinoma / Q000235:genetics* / Q000628:therapy; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D018284:Cystadenocarcinoma, Serous / Q000235:genetics; D005260:Female; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D015316:Genetic Therapy / Q000379:methods; D025743:HMGA2 Protein / Q000235:genetics*; D006801:Humans; D017403:In Situ Hybridization; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000628:therapy; D034741:RNA, Small Interfering / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D014183:Transplantation, Heterologous; D015854:Up-Regulation
D025743:HMGA2 Protein; D034741:RNA, Small Interfering